News and Announcements
Hot Calibration Run of the OncoSil Device
- Published August 18, 2016 4:24PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th August 2016, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical or the Company), a late stage medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to announce that it has successfully completed a supply chain validation process including the first hot (radioactive) calibration delivery of OncoSil™.
In preparation for the commencement of the Company’s planned global clinical study of OncoSil™ for the treatment of pancreatic cancer (Oncopac-1) and the commercialisation of OncoSil™ subject to attainment of CE Mark, the Company restarted de-novo manufacturing of OncoSil™ microparticles in January 2016. The manufacturing, supply chain validation and delivery to clinical and commercial centres of OncoSil™ product is a key step to commercial sales and the treatment of patients in the OncoPac-1 Study.
To view the full announcement, please click on the button below.